These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 34208964)

  • 21. Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions.
    Detjen K; Hammerich L; Özdirik B; Demir M; Wiedenmann B; Tacke F; Jann H; Roderburg C
    Neuroendocrinology; 2021; 111(3):217-236. PubMed ID: 32615560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
    Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)].
    Klöppel G
    Pathologe; 2019 May; 40(3):211-219. PubMed ID: 30969346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic role and prognostic value of tumor markers in high-grade gastro-enteropancreatic neuroendocrine neoplasms.
    Gao C; Fan Z; Yang J; Shi M; Li Y; Zhan H
    Pancreatology; 2023 Mar; 23(2):204-212. PubMed ID: 36710224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
    Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
    Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pathological characteristics and survival analysis of 355 patients with gastroenteropancreatic neuroendocrine neoplasms].
    Li Y; Wang YF; Tan BB; Er LM; Zhao Q; Fan LQ; Zhang ZD; Liu Y
    Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):426-431. PubMed ID: 32482035
    [No Abstract]   [Full Text] [Related]  

  • 27. Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).
    Puccini A; Poorman K; Salem ME; Soldato D; Seeber A; Goldberg RM; Shields AF; Xiu J; Battaglin F; Berger MD; Tokunaga R; Naseem M; Barzi A; Iqbal S; Zhang W; Soni S; Hwang JJ; Philip PA; Sciallero S; Korn WM; Marshall JL; Lenz HJ
    Clin Cancer Res; 2020 Nov; 26(22):5943-5951. PubMed ID: 32883742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification.
    Xu JX; Wu DH; Ying LW; Hu HG
    World J Gastroenterol; 2021 Dec; 27(47):8123-8137. PubMed ID: 35068858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long Non-coding RNAs in Pulmonary Neuroendocrine Neoplasms.
    Narayanan D; Mandal R; Hardin H; Chanana V; Schwalbe M; Rosenbaum J; Buehler D; Lloyd RV
    Endocr Pathol; 2020 Sep; 31(3):254-263. PubMed ID: 32388776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surgical outcomes of gastro-entero-pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma.
    Li MX; Lopez-Aguiar AG; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Zhang XF; Pawlik TM
    J Surg Oncol; 2022 Sep; 126(4):689-697. PubMed ID: 35616186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
    Fazio N; Milione M
    Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The diagnosis and treatment of G3 neuroendocrine tumors according to the new NCCN guideline].
    Liang Y; Yu XJ; Chen J
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(14):982-987. PubMed ID: 35399015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) - Current literature review of diagnostics and therapy. What has changed in the management?
    Jurkiewicz K; Miciak M; Kaliszewski K
    Pol Przegl Chir; 2024 Mar; 96(4):58-66. PubMed ID: 39138986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3.
    Ali AS; Langer SW; Federspiel B; Hjortland GO; Grønbæk H; Ladekarl M; Welin S; Weber Vestermark L; Arola J; Osterlund P; Knigge U; Sørbye H; Micke P; Grimelius L; Grönberg M; Tiensuu Janson E
    PLoS One; 2020; 15(12):e0243900. PubMed ID: 33315908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF
    Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
    Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peritoneal Carcinomatosis in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Clinical Impact and Effectiveness of the Available Therapeutic Options.
    Merola E; Prasad V; Pascher A; Pape UF; Arsenic R; Denecke T; Fehrenbach U; Wiedenmann B; Pavel ME
    Neuroendocrinology; 2020; 110(6):517-524. PubMed ID: 31484182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TCF-3-mediated transcription of lncRNA HNF1A-AS1 targeting oncostatin M expression inhibits epithelial-mesenchymal transition via TGFβ signaling in gastroenteropancreatic neuroendocrine neoplasms.
    Xue J; Bai J; Long Q; Wei Y; Pan J; Li X; Tang Q
    Aging (Albany NY); 2021 May; 13(10):14065-14077. PubMed ID: 34037532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia.
    Bösch F; Brüwer K; Altendorf-Hofmann A; Auernhammer CJ; Spitzweg C; Westphalen CB; Boeck S; Schubert-Fritschle G; Werner J; Heinemann V; Kirchner T; Angele M; Knösel T
    Endocr Relat Cancer; 2019 Mar; 26(3):293-301. PubMed ID: 30608901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study.
    Zhang X; Ma L; Bao H; Zhang J; Wang Z; Gong P
    BMC Endocr Disord; 2014 Jul; 14():54. PubMed ID: 25001493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are G3 ENETS neuroendocrine neoplasms heterogeneous?
    Vélayoudom-Céphise FL; Duvillard P; Foucan L; Hadoux J; Chougnet CN; Leboulleux S; Malka D; Guigay J; Goere D; Debaere T; Caramella C; Schlumberger M; Planchard D; Elias D; Ducreux M; Scoazec JY; Baudin E
    Endocr Relat Cancer; 2013 Oct; 20(5):649-57. PubMed ID: 23845449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.